Sunday, 4 November 2012

Research: Human neural stem cells can myelinate


Shiverer-immunodeficient (Shi-id) mice demonstrate defective myelination in the central nervous system (CNS) and significant ataxia (unsteadiness of gait) by 2 to 3 weeks of life. Expanded, banked human neural stem cells (HuCNS-SCs) were transplanted into three sites in the brains of juvenile Shi-id mice, which were asymptomatic or showed advanced hypomyelination (reduced myelination) , respectively. In both groups of mice, HuCNS-SCs engrafted and underwent preferential differentiation into oligodendrocytes. These oligodendrocytes generated compact myelin with normalized nodal organization, ultrastructure, and axon conduction velocities (speed of electrical conduction). Myelination was equivalent in neonatal and juvenile mice by quantitative histopathology and high-field ex vivo magnetic resonance imaging, which, through fractional anisotropy, revealed CNS myelination 5 to 7 weeks after HuCNS-SC transplantation. Transplanted HuCNS-SCs generated functional myelin in the CNS, even in animals with severe symptomatic hypomyelination, suggesting that this strategy may be useful for treating dysmyelinating diseases.


Shiverer mice have a mutation in myelin basic protein that makes them not myelinate properly and they get a neurological problem that they shake or shiver. In this study they have used human stem cells and transplanted them into mice and the have become myelin forming cells. This is good news. The next important step would be to see if these cells  can do the same in an inflamed lesion like that that could be encountered in MS.  This experiment repeats what similar studies have shown.

6 comments:

  1. Alemtuzumab has been associated with infusion-related events including hypotension, rigors, fever, shortness of breath, bronchospasm, chills, and/or rash. In post-marketing reports, the following serious infusion-related events were reported: syncope, pulmonary infiltrates, ARDS, respiratory arrest, cardiac arrhythmias, myocardial infarction and cardiac arrest. The cardiac adverse events have resulted in death in some cases. This DRUG is VERY dangerous AND BEING PROMOTED

    ReplyDelete
    Replies
    1. I’m as sceptical about DMTs as the next person, however, people must no troll.

      We have the right to disagree but you can’t start this infuriating spamming campaign. It undermines mine and your argument, making both look foolish. That’s not how things work.

      If you don’t agree with DMTs then you have a responsibility to intelligently present you viewpoint, as do the other party.

      As someone who thinks DMTs are about as useful as CCSVI, I guess I have a responsibility to argue against both. At least DMTs have been scientifically assessed, which is more than I can say about CCSVI. At the end of the day they both generate mass profit at great risk.

      Delete
    2. Are you talking about the use of alemtuzumab in leukaemia patients leading to these adverse events, rather than the use in MSers? Alemtuzumab is used in much greater amounts in leukaemia patients. I don't think any of the trials for ms and alemtuzumab mentioned these events as happening to their cohort. Eating too much rhubarb is dangerous, but you're not suggesting we ban that as well?

      Delete
    3. This is trolling and the person doing this is just irriatating every one!. Stop it! If you have comments fine but they do not need to be posted every where. Spend your energies being productive.

      If you have concerns about the safety of drugs fine, but this from of post does nothing to support, your cause which we know based on you MO.

      Delete
  2. Stem cell research is the way. This is encouraging news. We need to get them out of the laboratory and into OUR central nervous systems.

    Yours,

    Impatient, Southend.

    ReplyDelete

Please note that all comments are moderated and any personal or marketing-related submissions will not be shown.